Compound News and Research

RSS

Promising new natural treatment for Alzheimer's disease nears clinical trial

A promising new natural treatment for Alzheimer's disease is moving toward clinical trials. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer's.

12 Mar 2015

McGill researchers discover that lots of useful medical information getting lost

Lots of potentially useful medical information is getting lost. McGill researchers discovered this when they looked into the lack of reporting of information from "stalled drug" trials in cancer, cardiovascular and neurological diseases.

12 Mar 2015

Two researchers win Humanity in Science prize for developing new antimalarial drug production methods

Prof. Dr. Peter H. Seeberger, a director at the Max Planck Institute of Colloids and Interfaces in Potsdam and a professor of chemistry at Freie Universität Berlin, and Prof. Dr.-Ing. Andreas Seidel-Morgenstern, a director at the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg and a professor of chemical engineering at the Otto-von Guericke-University in Magdeburg, won the Humanity in Science prize for their groundbreaking work in developing new production methods for antimalarial drugs.

12 Mar 2015

Green Cross makes investment in cell therapy sector in China

Green Cross, a South Korean biopharmaceutical company, today announced that it had signed MOU on the 6th of March with the Guizhou provincial government of China for the investment in the cell therapy sector in China.

11 Mar 2015

New drug shows promise in driving insulin-producing beta cells to multiply

In a screen of more than 100,000 potential drugs, only one, harmine, drove human insulin-producing beta cells to multiply, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai, funded by JDRF and the National Institutes of Health, and published online today in Nature Medicine.

10 Mar 2015

Researchers identify new class of drugs that slows aging process

A research team from The Scripps Research Institute, Mayo Clinic and other institutions has identified a new class of drugs that in animal models dramatically slows the aging process—alleviating symptoms of frailty, improving cardiac function and extending a healthy lifespan.

10 Mar 2015

Viagra can have anti-cancer, anti-Alzheimer's disease effects if used with new drugs

Chaperone proteins play an important role in protein folding in human cells and in bacteria and are promising new targets for drugs to treat cancer and Alzheimer's disease and for novel antiviral drugs and antibiotics. How existing drugs such as Viagra or Cialis and a derivative of the drug Celebrex, for example, can reduce the activity of a specific chaperone protein, with the potential for anti-tumor and anti-Alzheimer's disease effects, is described in a Review article in DNA and Cell Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

10 Mar 2015

Naturally-occurring protein in the brain can curb binge alcohol drinking

A new study led by University of North Carolina School of Medicine researchers has found that a naturally-occurring protein in the brain can act to suppress binge alcohol drinking, a major public health problem estimated to cost the U.S. more than $170 billion each year.

10 Mar 2015

Suicide rates for U.S. youths nearly double in rural areas

The adolescent and young-adult suicide rate in the United States was almost twice as high in rural settings than in urban areas between 1996 and 2010, and new research suggests that the gap appears to be widening.

10 Mar 2015

EMD Serono executes amendment agreement with Opexa for development of Tcelna (imilecleucel-T)

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).

9 Mar 2015

CPRIT awards research and recruitment grants to improve cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center researchers more than $7.5 million in research grants to improve diagnostic and therapeutic services and research relating to cancers of the brain, breast, throat, and bone, as well as to improve scientific understanding of cancer biology.

9 Mar 2015

Obesity drug under clinical trials could help treat anxiety

Did you know that our body produces its own marijuana-like compound to protect us against anxiety? A study led by Ottawa researchers, published today in Neuron, reveals a new biological pathway that regulates this system and suggests that a drug currently in clinical trials to treat obesity might also provide an attractive way to combat anxiety disorders.

6 Mar 2015

Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A

Bayer HealthCare today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for BAY 81-8973, a recombinant Factor VIII compound. Bayer is seeking FDA approval of the investigational compound, proposed trade name Kovaltry, for the treatment of hemophilia A in children and adults.

4 Mar 2015

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer.

4 Mar 2015

New antibody provides 100% protection against H5N1 influenza virus in animal models

Since 2003, the H5N1 influenza virus, more commonly known as the bird flu, has been responsible for the deaths of millions of chickens and ducks and has infected more than 650 people, leading to a 60 percent mortality rate for the latter. Luckily, this virus has yet to achieve human-to-human transmission, but a small number of mutations could change that, resulting in a pandemic.

4 Mar 2015

Study on spider venom may lead to new class of potent painkillers

New research shows that seven compounds of the countless found in spider venom block a key step in the body's ability to pass pain signals to the brain. The hunt for a medicine based on just one of these compounds, which would open up a new class of potent painkillers, is now a step closer according to new research published in the British Journal of Pharmacology.

4 Mar 2015

Rigel Pharmaceuticals reports net loss of $22.3 million for fourth quarter 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013.

3 Mar 2015

SCIEX and Labor Berlin Collaboration to Advance Forensic Testing

SCIEX announced today a research collaboration with Labor Berlin, the largest clinical laboratory in Germany, for the development of a hybrid Quadrupole Time-of-Flight (TOF) MS/MS reference library of relevant forensic chemical compounds

3 Mar 2015

TREM2 protein may help slow progression of multiple sclerosis, Alzheimer's disease

Highlighting a potential target in the treatment of multiple sclerosis (MS) and Alzheimer's disease, new research suggests that triggering a protein found on the surface of brain cells may help slow the progression of these and other neurological diseases.

3 Mar 2015

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed.

28 Feb 2015